Copyright Reports & Markets. All rights reserved.

Global Metastatic Prostate Cancer Treatment Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Metastatic Prostate Cancer Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Mono
    • 1.2.3 Combination
    • 1.2.4 Mono/Combination
  • 1.3 Market by Application
    • 1.3.1 Global Metastatic Prostate Cancer Treatment Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Hospital
    • 1.3.3 Drug Store
    • 1.3.4 Online Pharmacy
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Metastatic Prostate Cancer Treatment Market Perspective (2016-2027)
  • 2.2 Metastatic Prostate Cancer Treatment Growth Trends by Regions
    • 2.2.1 Metastatic Prostate Cancer Treatment Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Metastatic Prostate Cancer Treatment Historic Market Share by Regions (2016-2021)
    • 2.2.3 Metastatic Prostate Cancer Treatment Forecasted Market Size by Regions (2022-2027)
  • 2.3 Metastatic Prostate Cancer Treatment Industry Dynamic
    • 2.3.1 Metastatic Prostate Cancer Treatment Market Trends
    • 2.3.2 Metastatic Prostate Cancer Treatment Market Drivers
    • 2.3.3 Metastatic Prostate Cancer Treatment Market Challenges
    • 2.3.4 Metastatic Prostate Cancer Treatment Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Metastatic Prostate Cancer Treatment Players by Revenue
    • 3.1.1 Global Top Metastatic Prostate Cancer Treatment Players by Revenue (2016-2021)
    • 3.1.2 Global Metastatic Prostate Cancer Treatment Revenue Market Share by Players (2016-2021)
  • 3.2 Global Metastatic Prostate Cancer Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Metastatic Prostate Cancer Treatment Revenue
  • 3.4 Global Metastatic Prostate Cancer Treatment Market Concentration Ratio
    • 3.4.1 Global Metastatic Prostate Cancer Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Metastatic Prostate Cancer Treatment Revenue in 2020
  • 3.5 Metastatic Prostate Cancer Treatment Key Players Head office and Area Served
  • 3.6 Key Players Metastatic Prostate Cancer Treatment Product Solution and Service
  • 3.7 Date of Enter into Metastatic Prostate Cancer Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Metastatic Prostate Cancer Treatment Breakdown Data by Type

  • 4.1 Global Metastatic Prostate Cancer Treatment Historic Market Size by Type (2016-2021)
  • 4.2 Global Metastatic Prostate Cancer Treatment Forecasted Market Size by Type (2022-2027)

5 Metastatic Prostate Cancer Treatment Breakdown Data by Application

  • 5.1 Global Metastatic Prostate Cancer Treatment Historic Market Size by Application (2016-2021)
  • 5.2 Global Metastatic Prostate Cancer Treatment Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Metastatic Prostate Cancer Treatment Market Size (2016-2027)
  • 6.2 North America Metastatic Prostate Cancer Treatment Market Size by Type
    • 6.2.1 North America Metastatic Prostate Cancer Treatment Market Size by Type (2016-2021)
    • 6.2.2 North America Metastatic Prostate Cancer Treatment Market Size by Type (2022-2027)
    • 6.2.3 North America Metastatic Prostate Cancer Treatment Market Size by Type (2016-2027)
  • 6.3 North America Metastatic Prostate Cancer Treatment Market Size by Application
    • 6.3.1 North America Metastatic Prostate Cancer Treatment Market Size by Application (2016-2021)
    • 6.3.2 North America Metastatic Prostate Cancer Treatment Market Size by Application (2022-2027)
    • 6.3.3 North America Metastatic Prostate Cancer Treatment Market Size by Application (2016-2027)
  • 6.4 North America Metastatic Prostate Cancer Treatment Market Size by Country
    • 6.4.1 North America Metastatic Prostate Cancer Treatment Market Size by Country (2016-2021)
    • 6.4.2 North America Metastatic Prostate Cancer Treatment Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Metastatic Prostate Cancer Treatment Market Size (2016-2027)
  • 7.2 Europe Metastatic Prostate Cancer Treatment Market Size by Type
    • 7.2.1 Europe Metastatic Prostate Cancer Treatment Market Size by Type (2016-2021)
    • 7.2.2 Europe Metastatic Prostate Cancer Treatment Market Size by Type (2022-2027)
    • 7.2.3 Europe Metastatic Prostate Cancer Treatment Market Size by Type (2016-2027)
  • 7.3 Europe Metastatic Prostate Cancer Treatment Market Size by Application
    • 7.3.1 Europe Metastatic Prostate Cancer Treatment Market Size by Application (2016-2021)
    • 7.3.2 Europe Metastatic Prostate Cancer Treatment Market Size by Application (2022-2027)
    • 7.3.3 Europe Metastatic Prostate Cancer Treatment Market Size by Application (2016-2027)
  • 7.4 Europe Metastatic Prostate Cancer Treatment Market Size by Country
    • 7.4.1 Europe Metastatic Prostate Cancer Treatment Market Size by Country (2016-2021)
    • 7.4.2 Europe Metastatic Prostate Cancer Treatment Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Metastatic Prostate Cancer Treatment Market Size (2016-2027)
  • 8.2 Asia-Pacific Metastatic Prostate Cancer Treatment Market Size by Type
    • 8.2.1 Asia-Pacific Metastatic Prostate Cancer Treatment Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Metastatic Prostate Cancer Treatment Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Metastatic Prostate Cancer Treatment Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Metastatic Prostate Cancer Treatment Market Size by Application
    • 8.3.1 Asia-Pacific Metastatic Prostate Cancer Treatment Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Metastatic Prostate Cancer Treatment Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Metastatic Prostate Cancer Treatment Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Metastatic Prostate Cancer Treatment Market Size by Region
    • 8.4.1 Asia-Pacific Metastatic Prostate Cancer Treatment Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Metastatic Prostate Cancer Treatment Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Metastatic Prostate Cancer Treatment Market Size (2016-2027)
  • 9.2 Latin America Metastatic Prostate Cancer Treatment Market Size by Type
    • 9.2.1 Latin America Metastatic Prostate Cancer Treatment Market Size by Type (2016-2021)
    • 9.2.2 Latin America Metastatic Prostate Cancer Treatment Market Size by Type (2022-2027)
    • 9.2.3 Latin America Metastatic Prostate Cancer Treatment Market Size by Type (2016-2027)
  • 9.3 Latin America Metastatic Prostate Cancer Treatment Market Size by Application
    • 9.3.1 Latin America Metastatic Prostate Cancer Treatment Market Size by Application (2016-2021)
    • 9.3.2 Latin America Metastatic Prostate Cancer Treatment Market Size by Application (2022-2027)
    • 9.3.3 Latin America Metastatic Prostate Cancer Treatment Market Size by Application (2016-2027)
  • 9.4 Latin America Metastatic Prostate Cancer Treatment Market Size by Country
    • 9.4.1 Latin America Metastatic Prostate Cancer Treatment Market Size by Country (2016-2021)
    • 9.4.2 Latin America Metastatic Prostate Cancer Treatment Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Metastatic Prostate Cancer Treatment Market Size (2016-2027)
  • 10.2 Middle East & Africa Metastatic Prostate Cancer Treatment Market Size by Type
    • 10.2.1 Middle East & Africa Metastatic Prostate Cancer Treatment Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Metastatic Prostate Cancer Treatment Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Metastatic Prostate Cancer Treatment Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Metastatic Prostate Cancer Treatment Market Size by Application
    • 10.3.1 Middle East & Africa Metastatic Prostate Cancer Treatment Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Metastatic Prostate Cancer Treatment Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Metastatic Prostate Cancer Treatment Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Metastatic Prostate Cancer Treatment Market Size by Country
    • 10.4.1 Middle East & Africa Metastatic Prostate Cancer Treatment Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Metastatic Prostate Cancer Treatment Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 AB Science
    • 11.1.1 AB Science Company Details
    • 11.1.2 AB Science Business Overview
    • 11.1.3 AB Science Metastatic Prostate Cancer Treatment Introduction
    • 11.1.4 AB Science Revenue in Metastatic Prostate Cancer Treatment Business (2016-2021)
    • 11.1.5 AB Science Recent Development
  • 11.2 BeiGene
    • 11.2.1 BeiGene Company Details
    • 11.2.2 BeiGene Business Overview
    • 11.2.3 BeiGene Metastatic Prostate Cancer Treatment Introduction
    • 11.2.4 BeiGene Revenue in Metastatic Prostate Cancer Treatment Business (2016-2021)
    • 11.2.5 BeiGene Recent Development
  • 11.3 eFFECTOR Therapeutics
    • 11.3.1 eFFECTOR Therapeutics Company Details
    • 11.3.2 eFFECTOR Therapeutics Business Overview
    • 11.3.3 eFFECTOR Therapeutics Metastatic Prostate Cancer Treatment Introduction
    • 11.3.4 eFFECTOR Therapeutics Revenue in Metastatic Prostate Cancer Treatment Business (2016-2021)
    • 11.3.5 eFFECTOR Therapeutics Recent Development
  • 11.4 Immunomedics(Gilead Sciences, Inc.)
    • 11.4.1 Immunomedics(Gilead Sciences, Inc.) Company Details
    • 11.4.2 Immunomedics(Gilead Sciences, Inc.) Business Overview
    • 11.4.3 Immunomedics(Gilead Sciences, Inc.) Metastatic Prostate Cancer Treatment Introduction
    • 11.4.4 Immunomedics(Gilead Sciences, Inc.) Revenue in Metastatic Prostate Cancer Treatment Business (2016-2021)
    • 11.4.5 Immunomedics(Gilead Sciences, Inc.) Recent Development
  • 11.5 Myovant Biosciences
    • 11.5.1 Myovant Biosciences Company Details
    • 11.5.2 Myovant Biosciences Business Overview
    • 11.5.3 Myovant Biosciences Metastatic Prostate Cancer Treatment Introduction
    • 11.5.4 Myovant Biosciences Revenue in Metastatic Prostate Cancer Treatment Business (2016-2021)
    • 11.5.5 Myovant Biosciences Recent Development
  • 11.6 SeleXel
    • 11.6.1 SeleXel Company Details
    • 11.6.2 SeleXel Business Overview
    • 11.6.3 SeleXel Metastatic Prostate Cancer Treatment Introduction
    • 11.6.4 SeleXel Revenue in Metastatic Prostate Cancer Treatment Business (2016-2021)
    • 11.6.5 SeleXel Recent Development
  • 11.7 Zenith Epigenetics Ltd.
    • 11.7.1 Zenith Epigenetics Ltd. Company Details
    • 11.7.2 Zenith Epigenetics Ltd. Business Overview
    • 11.7.3 Zenith Epigenetics Ltd. Metastatic Prostate Cancer Treatment Introduction
    • 11.7.4 Zenith Epigenetics Ltd. Revenue in Metastatic Prostate Cancer Treatment Business (2016-2021)
    • 11.7.5 Zenith Epigenetics Ltd. Recent Development
  • 11.8 VasGene Therapeutics, Inc.
    • 11.8.1 VasGene Therapeutics, Inc. Company Details
    • 11.8.2 VasGene Therapeutics, Inc. Business Overview
    • 11.8.3 VasGene Therapeutics, Inc. Metastatic Prostate Cancer Treatment Introduction
    • 11.8.4 VasGene Therapeutics, Inc. Revenue in Metastatic Prostate Cancer Treatment Business (2016-2021)
    • 11.8.5 VasGene Therapeutics, Inc. Recent Development
  • 11.9 Telix Pharmaceuticals
    • 11.9.1 Telix Pharmaceuticals Company Details
    • 11.9.2 Telix Pharmaceuticals Business Overview
    • 11.9.3 Telix Pharmaceuticals Metastatic Prostate Cancer Treatment Introduction
    • 11.9.4 Telix Pharmaceuticals Revenue in Metastatic Prostate Cancer Treatment Business (2016-2021)
    • 11.9.5 Telix Pharmaceuticals Recent Development
  • 11.10 Arvinas Inc.
    • 11.10.1 Arvinas Inc. Company Details
    • 11.10.2 Arvinas Inc. Business Overview
    • 11.10.3 Arvinas Inc. Metastatic Prostate Cancer Treatment Introduction
    • 11.10.4 Arvinas Inc. Revenue in Metastatic Prostate Cancer Treatment Business (2016-2021)
    • 11.10.5 Arvinas Inc. Recent Development
  • 11.11 Amgen
    • 11.11.1 Amgen Company Details
    • 11.11.2 Amgen Business Overview
    • 11.11.3 Amgen Metastatic Prostate Cancer Treatment Introduction
    • 11.11.4 Amgen Revenue in Metastatic Prostate Cancer Treatment Business (2016-2021)
    • 11.11.5 Amgen Recent Development
  • 11.12 Genentech
    • 11.12.1 Genentech Company Details
    • 11.12.2 Genentech Business Overview
    • 11.12.3 Genentech Metastatic Prostate Cancer Treatment Introduction
    • 11.12.4 Genentech Revenue in Metastatic Prostate Cancer Treatment Business (2016-2021)
    • 11.12.5 Genentech Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Metastatic Prostate Cancer Treatment Scope and Market Size
    Metastatic Prostate Cancer Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Metastatic Prostate Cancer Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

    Segment by Type
    Mono
    Combination
    Mono/Combination

    Segment by Application
    Hospital
    Drug Store
    Online Pharmacy

    By Region
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    AB Science
    BeiGene
    eFFECTOR Therapeutics
    Immunomedics(Gilead Sciences, Inc.)
    Myovant Biosciences
    SeleXel
    Zenith Epigenetics Ltd.
    VasGene Therapeutics, Inc.
    Telix Pharmaceuticals
    Arvinas Inc.
    Amgen
    Genentech

    Buy now